Fish and method for producing fish
US-2020253173-A1 · Aug 13, 2020 · US
US12507679B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12507679-B2 |
| Application number | US-202217723159-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 18, 2022 |
| Priority date | Apr 16, 2021 |
| Publication date | Dec 30, 2025 |
| Grant date | Dec 30, 2025 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Descried in certain example embodiments herein are engineered fish, particularly engineered catfish, that are engineered to contain modified myostatin, melanocortin-4 receptor, and/or one or more n-3 fatty acid biosynthesis pathway genes and/or gene products.
Opening claim text (preview).
What is claimed is: 1 . An engineered fish of the genus Ictalurus whose genome comprises: a modified melanocortin-4 receptor gene or gene product, wherein the modified melanocortin-4 receptor gene or gene product has decreased or eliminated expression, activity, or both as compared to a suitable control; and an exogenous elongase gene, wherein the engineered fish of the genus Ictalurus has increased body weight, as compared to an engineered fish of the genus Ictalurus having only the modified melanocortin-4 receptor gene or gene product, and wherein the exogenous elongase gene is inserted into the melanocortin-4 receptor gene such that at least a portion of exon 1 or the entirety of the melanocortin-4 receptor gene is replaced with the exogenous elongase gene. 2 . The engineered fish of claim 1 , further comprising a modified myostatin gene or gene product, wherein the modified myostatin gene or gene product has decreased or eliminated expression, activity, or both as compared to the suitable control. 3 . The engineered fish of claim 1 , wherein the engineered fish has increased body weight, increased body mass, increased growth rate, increased amount of n-3 fatty acids, sterility, or any combination thereof as compared to a suitable control. 4 . The engineered fish of claim 1 , wherein the modified melanocortin-4 receptor gene or gene product expression, activity, or both are each decreased 2-1000 fold. 5 . The engineered fish of claim 2 , wherein the modified melanocortin-4 receptor gene or gene product expression, activity, or both are each independently decreased 2-1000 fold, wherein the myostatin gene or gene product expression, activity, or both, are each independently decreased 2-1000 fold, or both. 6 . The engineered fish of claim 2 , wherein a second exogenous gene is inserted into the myostatin gene such that at least a portion of or the entirety of the myostatin gene is replaced with the exogenous gene to generate the modified myostatin gene. 7 . The engineered fish of claim 6 , wherein the engineered fish has increased amount of docosahexaenoic acid in one or more cells or tissues, increased amount of eicosapentaenoic acid in one or more cells or tissues, increased disease resistance, or any combination thereof as compared to a suitable control. 8 . The engineered fish of claim 2 , wherein the engineered fish has increased body mass, increased growth rate, increased amount of docosahexaenoic acid in one or more cells or tissues, increased amount of eicosapentaenoic acid in one or more cells or tissues, increased disease resistance, or any combination thereof as compared to a suitable control. 9 . The engineered fish of claim 1 , wherein the engineered fish has increased body mass, increased growth rate, increased amount of docosahexaenoic acid in one or more cells or tissues, increased amount of eicosapentaenoic acid in one or more cells or tissues, or any combination thereof as compared to a suitable control. 10 . The engineered fish of claim 1 , wherein the engineered fish is I. punctatus, I. furcatus , or is a hybrid thereof. 11 . The engineered fish of claim 1 , wherein the modified melanocortin-4 receptor A gene or gene product is produced using a programmable nuclease system. 12 . The engineered fish of claim 11 , wherein the programmable nuclease system is a CRISPR-Cas system, a TALEN system, a Zinc Finger Nuclease system, or an IscB system. 13 . A feed or food product comprising: an engineered fish or portion thereof, wherein the engineered fish is an engineered fish according to claim 1 .
from fish · CPC title
inducing loss of function · CPC title
Fish · CPC title
involving nucleic acids · CPC title
G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.